When does tirzepatide’s patent protection end?
Tirzepatide (Eli Lilly’s Mounjaro/Zepbound) does not have a single “one date” for everyone. Patent protection typically ends in phases because different patents cover different aspects (for example, specific formulations, methods of use, or combinations), and different countries have their own patent terms and expiry dates.
The exact “off patent” date for tirzepatide therefore depends on:
- the country you mean (US vs EU vs UK, etc.),
- which specific patent(s) are relevant, and
- whether you’re asking about the first generic opportunity or the full end of exclusivity (which can be extended beyond the primary patent term).
What do DrugPatentWatch and patent trackers usually say about tirzepatide?
For investors, researchers, and generic competitors, DrugPatentWatch.com is a common starting point because it tracks which patents are listed for tirzepatide and shows projected expiry timing by market. You can use it to identify the likely “latest” relevant expiry that could delay generic entry. Check the tirzepatide listing here: https://www.drugpatentwatch.com/ .
Can generics or biosimilars launch as soon as a patent expires?
Even after key patents expire, regulators can still block generic entry if:
- other related patents (method-of-use, formulation) are still in force,
- data exclusivity or other regulatory protections remain active, or
- litigation leads to a delayed launch.
So “comes off patent” is best interpreted as the point when the last relevant patent barrier ends, but the first launch date can still be later depending on the exclusivity and legal landscape.
What country should you look up to get the exact date?
If you tell me the market (for example, “US only” or “EU”), I can narrow the answer to the applicable patent expiry timing for that jurisdiction using the listed patent information (including the timing shown on DrugPatentWatch.com).
Sources
- DrugPatentWatch.com